Sab biotherapeutics presents positive phase 1 and 2a data for sab-176 influenza immunotherapy at isirv-avg conference

First fully-human multi-epitope binding broadly neutralizing immunoglobulin antibody therapeutic being developed for treatment of high-risk patients demonstrates safety and efficacy in phase 1 and 2a trials

SABS Ratings Summary

SABS Quant Ranking